Vomiting on Wegovy® tablets

The tablet’s own vomiting numbers

OASIS 4 enrolled adults without diabetes and gave them either the 25 mg tablet or a matching placebo every day for 64 weeks, after a 12-week climb in strength. ^[1] The published abstract reports digestive adverse events overall in 74.0% versus 42.2%, but not vomiting on its own. ^[4] The vomiting figure appears in two other places: the EU product information for the tablets and the results the sponsor posted to ClinicalTrials.gov. ^[2][3]

The US label handles the tablet differently. It describes the trial (Study 7), then says the types and frequency of common adverse reactions were similar to those in Table 3, which comes from three trials of the 2.4 mg injection and lists reactions seen in at least 2% of people and more often than on placebo. ^[1] The injection row is shown below for orientation only.

If the tablet comes back up

This is the question people ask most about a daily pill, and the honest answer is that the US label, the EU product information and the EU patient leaflet do not address it. They do not say to take another tablet, and they do not say the dose is lost. ^[1][2]

What they do set out is a framework. The label allows one tablet a day, swallowed whole, and if a dose is missed it is skipped and the next one taken the following day. ^[1] The EU text repeats the skip rule and says more than one tablet a day should not be taken to reach the effect of a higher strength. ^[2] On absorption, the label says it happens mainly in the stomach and that blood levels peak about an hour after the dose; the EU document adds that semaglutide’s half-life is about a week and that daily dosing combined with that long half-life smooths out day-to-day swings. ^[1][2] Neither document turns these facts into a rule about a tablet that was vomited.

So the sensible move is to ask rather than improvise. Note the time you took the tablet and the time you were sick, and put the question to your pharmacist or prescriber.

Severity, timing and who stopped

In the EU description of OASIS 4, nausea, vomiting, indigestion, diarrhoea and stomach pain were mostly mild to moderate and short-lived, and digestive events were reported most often during dose escalation. ^[2] The US label counts severe digestive reactions separately: 2% on the tablet and 0% on placebo, against 4.1% and 0.9% in the injection trials. ^[1]

Stopping for good because of a digestive reaction happened in 3.4% of the tablet group and 2% of the placebo group. ^[1] For adverse reactions of any kind, section 6.1 gives 6.9% versus 5.9%, while the clinical studies section (14) prints 6.8% versus 5.9% for the same trial, a small inconsistency within the label. ^[1] The registry’s list of serious adverse events, which is not limited by the 5% threshold, contains no vomiting, dehydration or kidney injury in the tablet group; the one acute kidney injury listed was in the placebo group. ^[3]

The climb itself is part of the label’s answer to stomach reactions: 1.5 mg for the first 30 days, then 4 mg, 9 mg and finally 25 mg from day 91, with the option for a prescriber to delay a step that is not tolerated. ^[1] The manufacturer’s pill guide asks you to tell your healthcare professional about side effects that bother you or persist before the next step. ^[8]

What a different dose showed

A second tablet trial, OASIS 1, tested oral semaglutide 50 mg, a strength that is not the approved US Wegovy® tablet. Its registry record lists vomiting in 80 of 334 people on 50 mg (24.0%) and 12 of 333 on placebo (3.6%) over weeks 0 to 75, and one serious dehydration event on semaglutide against none on placebo. ^[5]

That a higher dose in one trial produced a lower vomiting share than 25 mg did in another is a reminder of how much study design, populations and escalation schedules shape these numbers. It is not evidence that a higher dose is gentler, and the two trials cannot be ranked.

Fluid loss, blood pressure and the kidneys

Vomiting matters beyond comfort because of what it takes out of the body. Section 5.5 of the label describes reports after approval of sudden kidney injury, sometimes needing dialysis, mostly in people who had become dehydrated from nausea, vomiting or diarrhoea; prescribers are asked to check kidney function in people with such reactions, especially at the start and during dose increases. ^[1] Section 17 asks that patients take precautions against fluid depletion and promptly report persistent vomiting. ^[1]

The EU tablet text adds that dehydration can, rarely, worsen kidney function, that people with moderately reduced kidney function may have more digestive effects, and it lists low blood pressure and dizziness on standing as uncommon reactions. ^[2] MedlinePlus describes the early signs of dehydration as thirst, a dry mouth, passing little urine that is darker than usual, headache and cramps; dizziness, a racing heart, confusion and passing no urine point to severe dehydration. ^[7] The dedicated page on the tablet’s kidney warning covers this chain in more detail.

When vomiting is a sign of something else

• Stomach bugs, food poisoning, migraine, early pregnancy, kidney stone pain and heavy cannabis use are common causes; vomiting can also be an early sign of appendicitis, a bowel blockage or an ulcer. ^[6]
• Pancreatitis: severe stomach pain that does not ease, with or without vomiting, possibly reaching the back. In OASIS 4, acute pancreatitis occurred in 0% on the tablet and 1.0% on placebo, but the label still lists it as a serious risk. ^[1][2]
• Gallbladder trouble: the Medication Guide lists upper stomach pain, fever, yellow skin or eyes and clay-coloured stools. ^[1]
• Bowel obstruction: reported after approval with semaglutide, and described in the EU leaflet as severe constipation with stomach ache, bloating and vomiting. ^[1][2]
• Too much medicine: the Medication Guide says taking too much can cause severe nausea, severe vomiting and severe low blood sugar. ^[1]

Getting fluids back in

Once a cause is known, MedlinePlus describes drinking small amounts of clear liquid often as part of home care, and for dehydration it suggests sipping water, sucking ice cubes or drinking water or electrolyte drinks, and warns against salt tablets. ^[6][7] It also advises anyone with vomiting to drink plenty and not wait for signs of dehydration. ^[7] The Medication Guide makes the same point for Wegovy®: drinking fluids helps lower the chance of dehydration. ^[1]

The tablet’s small water allowance applies only to swallowing the dose and the 30 minutes after it. ^[1] If vomiting makes the morning routine impossible, or you cannot keep fluids down, that is a conversation for your prescriber the same day rather than something to work around alone.

Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.